BioWorld Asia

Sep. 23, 2009

Pieris Getting $10M Up Front in Allergan Ophthalmology Deal

Pieris AG is getting an up-front payment of $10 million from Allergan Inc., as part of a licensing deal under which the latter firm will gain access to its anticalin technology in ophthalmology indications. (BioWorld International) Read More

Wellcome Trust, Merck Team Up to Create £90M Vaccine Program

New Tools to Allow Deeper Scrutiny of Cancer-Fighting Cells

After Rebuffing Potential Suitor, Renovo Slashes Staffing, R&D

Cell Medica Raises £1.95M to Expand Cell Therapy Work

Signaling Systems the Focus on $22M Push in Systems Biology

AGI Therapeutics' New Strategy: Extending into Niche Markets

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for March 6, 2026.

Depression concept with human, broken brain and heavy rain

CROI 2026 highlights depression and cognitive vulnerability in HIV

BioWorld

The effects of aging pose an additional challenge for people with HIV due to the neurological and psychological consequences that persist despite antiretroviral...

News in brief

BioWorld Asia

BioWorld Asia briefs for March 3, 2026

University of Southern California reports new MAPT aggregation inhibitors

BioWorld Science

The University of Southern California has identified (2-oxo-2H-chromen-3-yl) scaffold-based carboxamide analogues acting as potent microtubule-associated protein...

Tanycytes in green capturing tau protein in red.

Brain’s hidden tau-clearing pathway uncovered

BioWorld Science

Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...